...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZHCLF trading
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Is ZCC is a long way off from topline results from where it now stands for it to be a buyout candidate?           Don't know!

ClinicalTrials.gov Identifier: NCT03901469

Official Title: A Phase 2 Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer
Actual Study Start Date : June 26, 2019
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : January 2022

 

Koo

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply